Jonathan D. Powell
Showed mTORC1 and mTORC2 steer which type of helper T cell a cell becomes
MD, PhD, Emory University School of Medicine · 20 years at Johns Hopkins University (Bloomberg-Kimmel Institute for Cancer Immunotherapy) · now Head of Development, Calico Life Sciences
Profile, Calico Life Sciences ↗
Portrait: Calico Life Sciences
Jonathan Powell spent two decades as a physician-scientist at Johns Hopkins, where his lab established mTOR as a central integrator of the metabolic and environmental signals that tell an immune cell what to become.
His group showed that mTOR differentially regulates effector and regulatory T cell lineage commitment, and that selective activation of mTORC1 versus mTORC2 signalling steers helper T cell differentiation — work that helped found the field of immunometabolism and pointed to mTOR as a target for both cancer immunotherapy and autoimmune disease. He now leads oncology development at Calico Life Sciences.
The timeline below follows Powell's contributions gathered in this Atlas.
Milestones in the Atlas
| Year | Evidence | Study |
|---|---|---|
| 2009 | M | The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment DEL2009 Shows mTOR differentially regulates effector and regulatory T cell lineage commitment. |
| 2011 | A | The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2 DEL2011 Shows mTOR regulates helper T cell differentiation through the selective activation of mTORC1 versus mTORC2 signalling. |
| 2011 | R | Regulation of immune responses by mTOR POW2011 Reviews how mTOR regulates immune responses, helping found the field of immunometabolism. |
On the programme
Meetings in the Atlas calendar where Jonathan D. Powell is listed among the speakers or organisers.
- upcoming Keystone Symposia: Tumor and Host Metabolism — Integrating Molecular, Cellular, and Systemic Interactions 2027 ↗ 7–10 Mar 2027 · Princeton, NJ, USA · Tier 2